Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094324484> ?p ?o ?g. }
- W3094324484 endingPage "2088" @default.
- W3094324484 startingPage "2078" @default.
- W3094324484 abstract "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a global pandemic and urgent treatment and prevention strategies are needed. Nitazoxanide, an anthelmintic drug, has been shown to exhibit in vitro activity against SARS-CoV-2. The present study used physiologically based pharmacokinetic (PBPK) modelling to inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported SARS-CoV-2 EC90 .A whole-body PBPK model was validated against available pharmacokinetic data for healthy individuals receiving single and multiple doses between 500 and 4000 mg with and without food. The validated model was used to predict doses expected to maintain tizoxanide plasma and lung concentrations above the EC90 in >90% of the simulated population. PopDes was used to estimate an optimal sparse sampling strategy for future clinical trials.The PBPK model was successfully validated against the reported human pharmacokinetics. The model predicted optimal doses of 1200 mg QID, 1600 mg TID and 2900 mg BID in the fasted state and 700 mg QID, 900 mg TID and 1400 mg BID when given with food. For BID regimens an optimal sparse sampling strategy of 0.25, 1, 3 and 12 hours post dose was estimated.The PBPK model predicted tizoxanide concentrations within doses of nitazoxanide already given to humans previously. The reported dosing strategies provide a rational basis for design of clinical trials with nitazoxanide for the treatment or prevention of SARS-CoV-2 infection. A concordant higher dose of nitazoxanide is now planned for investigation in the seamless phase I/IIa AGILE trial." @default.
- W3094324484 created "2020-10-29" @default.
- W3094324484 creator A5002515350 @default.
- W3094324484 creator A5007876312 @default.
- W3094324484 creator A5011598437 @default.
- W3094324484 creator A5013182750 @default.
- W3094324484 creator A5019065116 @default.
- W3094324484 creator A5030009340 @default.
- W3094324484 creator A5031927708 @default.
- W3094324484 creator A5041365930 @default.
- W3094324484 creator A5043022445 @default.
- W3094324484 creator A5049693794 @default.
- W3094324484 creator A5050429399 @default.
- W3094324484 creator A5052158257 @default.
- W3094324484 creator A5059972075 @default.
- W3094324484 creator A5060462160 @default.
- W3094324484 creator A5061182167 @default.
- W3094324484 creator A5066429649 @default.
- W3094324484 creator A5067891076 @default.
- W3094324484 creator A5070957694 @default.
- W3094324484 creator A5072204298 @default.
- W3094324484 creator A5080768595 @default.
- W3094324484 creator A5083526720 @default.
- W3094324484 creator A5085160612 @default.
- W3094324484 creator A5085499068 @default.
- W3094324484 date "2020-12-01" @default.
- W3094324484 modified "2023-10-16" @default.
- W3094324484 title "Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis" @default.
- W3094324484 cites W1520664895 @default.
- W3094324484 cites W1542069658 @default.
- W3094324484 cites W191673104 @default.
- W3094324484 cites W1967035954 @default.
- W3094324484 cites W1977092515 @default.
- W3094324484 cites W1989043263 @default.
- W3094324484 cites W1989673880 @default.
- W3094324484 cites W1993442326 @default.
- W3094324484 cites W2006101774 @default.
- W3094324484 cites W2017628668 @default.
- W3094324484 cites W2029590089 @default.
- W3094324484 cites W2041777107 @default.
- W3094324484 cites W2044289570 @default.
- W3094324484 cites W2057441748 @default.
- W3094324484 cites W2069839966 @default.
- W3094324484 cites W2086627198 @default.
- W3094324484 cites W2092237005 @default.
- W3094324484 cites W2106677606 @default.
- W3094324484 cites W2111150600 @default.
- W3094324484 cites W2113830209 @default.
- W3094324484 cites W2126313057 @default.
- W3094324484 cites W2142573506 @default.
- W3094324484 cites W2149272038 @default.
- W3094324484 cites W2153040535 @default.
- W3094324484 cites W2156140162 @default.
- W3094324484 cites W2156321359 @default.
- W3094324484 cites W2165334931 @default.
- W3094324484 cites W2278592283 @default.
- W3094324484 cites W2321252337 @default.
- W3094324484 cites W2335696673 @default.
- W3094324484 cites W2585379663 @default.
- W3094324484 cites W2746676899 @default.
- W3094324484 cites W2762848589 @default.
- W3094324484 cites W2886907866 @default.
- W3094324484 cites W2904034213 @default.
- W3094324484 cites W2904823773 @default.
- W3094324484 cites W2911991742 @default.
- W3094324484 cites W2923800168 @default.
- W3094324484 cites W2952473760 @default.
- W3094324484 cites W2987248305 @default.
- W3094324484 cites W3001897055 @default.
- W3094324484 cites W3005212621 @default.
- W3094324484 cites W3008295344 @default.
- W3094324484 cites W3009335299 @default.
- W3094324484 cites W3009577418 @default.
- W3094324484 cites W3009885589 @default.
- W3094324484 cites W3011802905 @default.
- W3094324484 cites W3012189167 @default.
- W3094324484 cites W3012655019 @default.
- W3094324484 cites W3013187757 @default.
- W3094324484 cites W3013369257 @default.
- W3094324484 cites W3013993630 @default.
- W3094324484 cites W3016084006 @default.
- W3094324484 cites W3020896479 @default.
- W3094324484 cites W3022213897 @default.
- W3094324484 cites W3025401836 @default.
- W3094324484 cites W3026711303 @default.
- W3094324484 cites W3030259932 @default.
- W3094324484 cites W3036409928 @default.
- W3094324484 cites W3041137986 @default.
- W3094324484 cites W3045079087 @default.
- W3094324484 cites W3094324484 @default.
- W3094324484 cites W3094797320 @default.
- W3094324484 doi "https://doi.org/10.1111/bcp.14619" @default.
- W3094324484 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8056737" @default.
- W3094324484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33085781" @default.
- W3094324484 hasPublicationYear "2020" @default.
- W3094324484 type Work @default.
- W3094324484 sameAs 3094324484 @default.
- W3094324484 citedByCount "39" @default.